inclusion criteria: 1. men and women aged 18 and over, diagnosed with coronavirus infection covid-19 after specific testing. when the course of the disease progressed to a severe degree, patients were excluded from the study; 2. signed consent to participate in the trial; 3. patients hospitalized with covid-19 disease. positive result of a pcr test (biomaterial - a swab from the nasopharynx and / or oropharynx) for infection with the sars-cov-2 virus within 72 hours on the day of screening. 4. patients with characteristic computed tomographic signs of the "ground-glass opacity" (one or two-sided spread) in combination with local foci of consolidation or without them; 5. oxygen therapy is not required, or oxygen therapy is required using a face mask or nasal cannulas; 6. the duration of the disease from the first symptoms to the day of screening is not more than 7 days; 7. the ability to understand the requirements for research participants, to give written consent to participate in the research (including the use and transfer of information about the health of patients, relevant to the research) and to follow the procedures specified in the research protocol.

inclusion criteria: 1. men and women aged 18 and over, diagnosed with coronavirus infection covid-19 after specific testing. when the course of the disease progressed to a severe degree, patients were excluded from the study; 2. signed consent to participate in the trial; 3. patients hospitalized with covid-19 disease. positive result of a pcr test (biomaterial - a swab from the nasopharynx and / or oropharynx) for infection with the sars-cov-2 virus within 72 hours on the day of screening. 4. patients with characteristic computed tomographic signs of the "ground-glass opacity" (one or two-sided spread) in combination with local foci of consolidation or without them; 5. oxygen therapy is not required, or oxygen therapy is required using a face mask or nasal cannulas; 6. the duration of the disease from the first symptoms to the day of screening is not more than 7 days; 7. the ability to understand the requirements for research participants, to give written consent to participate in the research (including the use and transfer of information about the health of patients, relevant to the research) and to follow the procedures specified in the research protocol.

inclusion criteria: men and women aged 18 and over, diagnosed with coronavirus infection covid-19 after specific testing. when the course of the disease progressed to a severe degree, patients were excluded from the study; signed consent to participate in the trial; patients hospitalized with covid-19 disease. positive result of a pcr test (biomaterial - a swab from the nasopharynx and / or oropharynx) for infection with the sars-cov-2 virus within 72 hours on the day of screening. patients with characteristic computed tomographic signs of the "ground-glass opacity" (one or two-sided spread) in combination with local foci of consolidation or without them; oxygen therapy is not required, or oxygen therapy is required using a face mask or nasal cannulas; the duration of the disease from the first symptoms to the day of screening is not more than 7 days; the ability to understand the requirements for research participants, to give written consent to participate in the research (including the use and transfer of information about the health of patients, relevant to the research) and to follow the procedures specified in the research protocol.

inclusion criteria: men and women aged 18 and over, diagnosed with coronavirus infection covid-19 after specific testing. when the course of the disease progressed to a severe degree, patients were excluded from the study; signed consent to participate in the trial; patients hospitalized with covid-19 disease. positive result of a pcr test (biomaterial - a swab from the nasopharynx and / or oropharynx) for infection with the sars-cov-2 virus within 72 hours on the day of screening. patients with characteristic computed tomographic signs of the "ground-glass opacity" (one or two-sided spread) in combination with local foci of consolidation or without them; oxygen therapy is not required, or oxygen therapy is required using a face mask or nasal cannulas; the duration of the disease from the first symptoms to the day of screening is not more than 7 days; the ability to understand the requirements for research participants, to give written consent to participate in the research (including the use and transfer of information about the health of patients, relevant to the research) and to follow the procedures specified in the research protocol.